Market Overview

KBI Biopharma BVBA Opens in Leuven, Belgium, Offering Analytical Services to the European Market

Share:

KBI Biopharma, Inc. announced today that its subsidiary KBI Biopharma
BVBA has begun operations at its newly completed laboratories in Leuven,
Belgium. The laboratories are co-located with JSR Life Sciences'
Amsphere™ A3 European manufacturing site and represent KBI's first
service offering based in Europe. KBI Biopharma BVBA initiated its first
client-sponsored programs in May 2018.

KBI Biopharma BVBA has capabilities for GMP and non-GMP services
including analytical development, formulation development,
biopharmaceutical characterization and cGMP quality control testing for
release and stability of drug substance and drug product.

"A key strength of this new facility is the utilization of our existing
procedures and knowledge base," said Cale Halbleib, PhD, Director of
Biopharmaceutical Development at KBI Biopharma BVBA. "Our Leuven site is
a European extension of KBI's well-established development and GMP
testing expertise. We can now leverage those capabilities in both the US
and EU including transfer and co-validation of analytical methods for
customers."

"The establishment of our analytical services laboratory in Belgium is a
key strategic objective for KBI," said President and CEO of KBI
Biopharma, Inc., Tim Kelly, PhD. "Through this expansion, we are
building on our exceptional foundation in analytical sciences to offer
an even more comprehensive solution to our client partners who seek to
conduct clinical trials and register their products in the EU and US."

To date, KBI has helped to advance more than 300 molecules in more than
70 unique health indications. By expanding its footprint into Europe,
KBI will continue to accelerate an even broader range of drug
development programs for its global client base.

About KBI Biopharma, Inc.

KBI Biopharma is a biopharmaceutical Contract Development &
Manufacturing Organization driven to accelerate the development of
innovative discoveries into life-changing biological products and expand
global access of medicines to patients in need.

From early-stage biotech to academic/non-profit organizations to many of
the world's largest pharmaceutical companies, KBI has served 300+
clients globally to accelerate and optimize their drug development
programs.

KBI's extensive track record of successful programs is a result of its
unique approach: applying the insight gained from our advanced
biophysical and analytical protein characterization techniques towards
the development of robust and scalable processes. KBI delivers
accelerated and integrated process development and cGMP
manufacturing programs
 for a wide range of recombinant protein
Active Pharmaceutical Ingredients (API) and cell therapies for our
clients.

KBI was founded in 1996 and operates facilities in Durham and Research
Triangle Park (NC), Boulder and Louisville (CO), The Woodlands (TX), San
Diego (CA), and Leuven, Belgium.

www.kbibiopharma.com

View Comments and Join the Discussion!